Clal Biotechnology Industries (XTAE:CBI) ROC % : 0.00% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Clal Biotechnology Industries's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 0.00%.

As of today (2024-06-10), Clal Biotechnology Industries's WACC % is 7.69%. Clal Biotechnology Industries's ROC % is -4.10% (calculated using TTM income statement data). Clal Biotechnology Industries earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Clal Biotechnology Industries ROC % Historical Data

The historical data trend for Clal Biotechnology Industries's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries ROC % Chart

Clal Biotechnology Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC %

Get a 7-Day Free Trial

-1.63

-2.36

-3.19

-4.57

-6.38

Clal Biotechnology Industries Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
ROC %	Get a 7-Day Free Trial															-20.55	-5.17	-7.51	-	-

Clal Biotechnology Industries ROC % Calculation

Clal Biotechnology Industries's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-10.181 * ( 1 - 0% )	/	( (169.369	+	149.755)	/ 2 )
=	-10.181	/	159.562
=	-6.38 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	182.69	-	0.436	-	( 12.885	-	max(0, 2.912	-	16.639	+	12.885	))
=	169.369

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	158.386	-	0.602	-	( 13.356	-	max(0, 6.662	-	14.691	+	13.356	))
=	149.755

Clal Biotechnology Industries's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	0 * ( 1 - 0% )	/	( (181.436	+	149.755)	/ 2 )
=	0	/	165.5955
=	0.00 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	194.987	-	3.752	-	( 10.52	-	max(0, 3.752	-	13.551	+	10.52	))
=	181.436

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	158.386	-	0.602	-	( 13.356	-	max(0, 6.662	-	14.691	+	13.356	))
=	149.755

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

Clal Biotechnology Industries (XTAE:CBI) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Clal Biotechnology Industries's WACC % is 7.69%. Clal Biotechnology Industries's ROC % is -4.10% (calculated using TTM income statement data). Clal Biotechnology Industries earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Clal Biotechnology Industries ROC % Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clal Biotechnology Industries (XTAE:CBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023

Website

http://www.cbi.co.il

Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.